A Phase I/IIa clinical trial is currently underway to evaluate CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma (106). This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.